Molecular Targeting Technologies

Molecular Targeting Technologies is a privately held, well-funded, clinical-stage biotechnology company developing targeted radiotherapies for rare cancers. MTTI has obtained a global exclusive license from the National Institutes of Health (NIH) to commercialize selected targeted radiopharmaceuticals covered by its Evans blue (EB) platform technology patents.